The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
 
Jing Wang
No Relationships to Disclose
 
Siqi Li
No Relationships to Disclose
 
Hao Jiang
No Relationships to Disclose
 
Ying-Jun Chang
No Relationships to Disclose
 
xiao-Su Zhao
No Relationships to Disclose
 
jin-Song Jia
No Relationships to Disclose
 
xiao-Lu Zhu
No Relationships to Disclose
 
li-Zhong Gong
No Relationships to Disclose
 
xiao-Hong Liu
No Relationships to Disclose
 
wen-Jing Yu
No Relationships to Disclose
 
xiao-Jun Huang
No Relationships to Disclose